Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis
View Full Paper
Ask AI
Bookmark
Share
Key result
In patients with cancer-associated acute venous thromboembolism, direct oral anticoagulants significantly reduced the risk of recurrent VTE (RR 0.62) compared with dalteparin, without a significantly higher likelihood of major bleeding.
Why the study?
Following the completion of a large trial comparing apixaban with dalteparin, an updated meta-analysis was needed to assess the efficacy and safety of DOACs versus LMWH in cancer-associated VTE.
Does the use of direct oral anticoagulants (DOACs) reduce recurrent VTE and major bleeding in adult patients with cancer-associated acute VTE compared to low-molecular-weight heparin (LMWH)?
Population
2,894 patients with cancer-associated VTE across four randomized controlled studies
Comparison
DOACs (apixaban, edoxaban, or rivaroxaban) vs dalteparin
Design
Systematic review and meta-analysis of randomized controlled trials
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Supports DOAC preference over LMWH for cancer-associated VTE; reinforces Level 1 evidence from aggregated trials.
Study Design
Type
Meta-Analysis (n=2,894)
Structured PICO
Does the use of direct oral anticoagulants (DOACs) reduce recurrent VTE and major bleeding in adult patients with cancer-associated acute VTE compared to low-molecular-weight heparin (LMWH)?
P
Population
2,894 adult patients with cancer-associated acute venous thromboembolism from 4 randomized controlled trials, evaluated for recurrent VTE and bleeding at 6 months.
I
Intervention
Direct oral anticoagulants (DOACs) as a class (apixaban, edoxaban, or rivaroxaban) administered orally for 6 to 12 months.
C
Comparator
Low-molecular-weight heparin (LMWH), specifically dalteparin (200 IU/kg daily for 1 month, followed by 150 IU/kg daily) administered subcutaneously.
O
Outcome
Two coprimary outcomes: recurrent VTE and major bleeding at 6 months.hard clinical
Main Result
Relative Risk: 0.62 (95% CI 0.43–0.91)
Absolute Event Rate: 5.2% vs 8.2%
In patients with cancer-associated VTE, DOACs are more effective than dalteparin for preventing recurrent VTE without a statistically significant increase in major bleeding, supporting their use as a preferred oral alternative.
Limitations
- Aggregated data meta-analysis preventing assessment of outcomes in patients with different types of cancer or baseline characteristics
- Results are limited to dalteparin alone as the comparator
- All included studies were open-label trials
- Subgroup analyses included considerably smaller patient cohorts, causing wide confidence intervals
- Absence of a direct comparison of the different DOACs to assess agent-specific safety profiles
- Different definitions of recurrent VTE across included studies may have led to differences in recurrence rates
Cite This Study
Giustozzi et al. (2020) conducted a meta-analysis in Acute venous thromboembolism associated with cancer (n=2,894). Direct Oral Anticoagulants (apixaban, edoxaban, or rivaroxaban) vs. Low-molecular-weight heparin (dalteparin) was evaluated on Recurrent VTE at 6 months (RR 0.62, 95% CI 0.43-0.91). In patients with cancer-associated acute venous thromboembolism, direct oral anticoagulants significantly reduced the risk of recurrent VTE (RR 0.62) compared with dalteparin, without a significantly higher likelihood of major bleeding.
Topics
View Full Paper
Ask AI
Bookmark
Share